Answers are grounded in this paper and cite their sources.
Therapeutic monoclonal antibodies (mAbs) accumulate a wide variety of chemical and post-translational modifications (PTMs) during production, storage, and in vivo after administration to patients. In this study, we applied size exclusion chromatography (SEC) to isolate subpopulations of different binding stoichiometries of mAb-target complexes after subjecting the mAbs to stresses relevant to manufacturing and physiological conditions. The SEC-fractionated subpopulations were analyzed by LC-MS/MS peptide mapping to identify critical PTMs that decrease ligand binding. Modifications in complementarity determining regions (CDRs) at light chain (LC) N33, heavy chain (HC) W103, and HC N104 were observed to be enriched in the SEC mAb fractions that did not bind the ligand, indicating these modifications diminish binding to the ligand. Total deamidation of N33 resulted in a moderate decrease in binding; however, when delineated into the individual D33 and isoD33 components via electron-transfer dissociation (ETD), only the isoD product was observed to significantly impact binding. Surface plasmon resonance (SPR), bead-based receptor–ligand binding, and cell-based receptor activation assays were utilized to measure the functional impact of the identified PTMs, which indicated a slight decrease in binding capacity and potency for the stressed mAbs, mirroring the trend observed by the SEC and LC-MS methods. The combination of the SEC assay and the traditional binding and potency assays provides a more complete view of the site-specific and modification-specific attributes in the context of their functional impact on decreased mAb–ligand binding and overall potency.
No takes yet. Share an insight, caveat, or question.
Woodall et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: